Mangoceuticals Statistics
Total Valuation
Mangoceuticals has a market cap or net worth of $5.61 million. The enterprise value is $5.40 million.
Important Dates
The next estimated earnings date is Tuesday, November 12, 2024, after market close.
| Earnings Date | Nov 12, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
Mangoceuticals has 2.37 million shares outstanding. The number of shares has increased by 55.07% in one year.
| Shares Outstanding | 2.37M |
| Shares Change (YoY) | +55.07% |
| Shares Change (QoQ) | +14.31% |
| Owned by Insiders (%) | 30.49% |
| Owned by Institutions (%) | 4.14% |
| Float | 1.64M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 3.86 |
| Forward PS | n/a |
| PB Ratio | 0.33 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 6.23 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.38, with a Debt / Equity ratio of 0.02.
| Current Ratio | 0.38 |
| Quick Ratio | 0.36 |
| Debt / Equity | 0.02 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -37.21 |
Financial Efficiency
Return on equity (ROE) is -108.44% and return on invested capital (ROIC) is -61.70%.
| Return on Equity (ROE) | -108.44% |
| Return on Assets (ROA) | -57.51% |
| Return on Capital (ROIC) | -61.70% |
| Revenue Per Employee | $288,931 |
| Profits Per Employee | -$3.04M |
| Employee Count | 3 |
| Asset Turnover | 0.09 |
| Inventory Turnover | 19.32 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -73.22% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | -73.22% |
| 50-Day Moving Average | 3.31 |
| 200-Day Moving Average | 4.24 |
| Relative Strength Index (RSI) | 37.03 |
| Average Volume (20 Days) | 359,453 |
Short Selling Information
The latest short interest is 310,304, so 13.11% of the outstanding shares have been sold short.
| Short Interest | 310,304 |
| Short Previous Month | 101,618 |
| Short % of Shares Out | 13.11% |
| Short % of Float | 18.86% |
| Short Ratio (days to cover) | 0.03 |
Income Statement
In the last 12 months, Mangoceuticals had revenue of $866,792 and -$9.13 million in losses. Loss per share was -$6.47.
| Revenue | 866,792 |
| Gross Profit | 504,362 |
| Operating Income | -8.53M |
| Pretax Income | -9.02M |
| Net Income | -9.13M |
| EBITDA | -8.51M |
| EBIT | -8.53M |
| Loss Per Share | -$6.47 |
Full Income StatementBalance Sheet
The company has $490,243 in cash and $285,045 in debt, giving a net cash position of $205,198 or $0.09 per share.
| Cash & Cash Equivalents | 490,243 |
| Total Debt | 285,045 |
| Net Cash | 205,198 |
| Net Cash Per Share | $0.09 |
| Equity (Book Value) | 13.83M |
| Book Value Per Share | 7.12 |
| Working Capital | -860,704 |
Full Balance SheetCash Flow
| Operating Cash Flow | -5.98M |
| Capital Expenditures | n/a |
| Free Cash Flow | -5.98M |
| FCF Per Share | -$2.53 |
Full Cash Flow StatementMargins
| Gross Margin | 58.19% |
| Operating Margin | -983.76% |
| Pretax Margin | -1,052.90% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | -731.32% |